quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:35:13·43d
INSIDERFiling
Entrada Therapeutics Inc. logo

SEC Form 4 filed by Entrada Therapeutics Inc.

TRDA· Entrada Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • TRDA
    Entrada Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 1UpdateCantor Fitzgerald-
  • Feb 11UpdateGuggenheim$20.00
  • Jan 28UpdateOppenheimer$21.00
  • Dec 6UpdateROTH MKM$29.00
  • Jan 5UpdateOppenheimer$22.00
  • Apr 3UpdateH.C. Wainwright$25.00

Related

  • INSIDER21d
    SEC Form 4 filed by Wentworth Kory James
  • ANALYST22d
    Cantor Fitzgerald initiated coverage on Entrada Therapeutics
  • INSIDER43d
    SEC Form 4 filed by Entrada Therapeutics Inc.
  • INSIDER48d
    Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)
  • INSIDER51d
    CEO Doshi Dipal was granted 139,400 shares and covered exercise/tax liability with 29,050 shares, increasing direct ownership by 27% to 526,014 units (SEC Form 4)
  • INSIDER51d
    Chief Financial Officer Wentworth Kory James was granted 44,600 shares and covered exercise/tax liability with 8,651 shares, increasing direct ownership by 33% to 145,975 units (SEC Form 4)
  • INSIDER51d
    President & COO Dowden Nathan J was granted 55,800 shares and covered exercise/tax liability with 21,261 shares, increasing direct ownership by 19% to 213,598 units (SEC Form 4)
  • INSIDER51d
    President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 11,475 shares and was granted 55,800 shares, increasing direct ownership by 22% to 242,224 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022